A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: You, Byung Chul, Kim, Young Seok, Kim, Hun il, Kim, Se Hun, Park, Seung Sik, Seo, Yu Ri, Kim, Sang Gyune, Lee, Se Whan, Kim, Hong Soo, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Korean Association for the Study of the Liver 2012
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467430/
https://ncbi.nlm.nih.gov/pubmed/23091807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2012.18.3.272
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia